Last updated: September 8, 2026
Bazedoxifene acetate and conjugated estrogens is marketed in the United States as DUAVEE by Pfizer. The oral combination contains conjugated estrogens 0.45 mg and bazedoxifene acetate equivalent to bazedoxifene 20 mg. FDA approved DUAVEE in 2013 for moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis in women with an intact uterus [1]. Its commercial position depends on a differentiated clinical proposition: estrogen symptom control without a progestin, using bazedoxifene as an estrogen agonist-antagonist to reduce endometrial stimulation.
The product has a narrow commercial base relative to estrogen-only and estrogen-progestin therapies. Its main advantages are the single-tablet regimen and avoidance of progestin exposure. Its principal disadvantages are price, boxed-warning hormone-therapy risks, limited prescribing volume, and eventual generic entry through the ANDA pathway. Pfizer does not separately disclose DUAVEE revenue in its public financial reporting, preventing a reliable product-level revenue estimate from company filings [2].
What drug is bazedoxifene acetate and conjugated estrogens?
DUAVEE combines an estrogen replacement component with a selective estrogen receptor modulator.
| Attribute |
DUAVEE |
| Active ingredients |
Conjugated estrogens and bazedoxifene acetate |
| Strength |
0.45 mg conjugated estrogens / 20 mg bazedoxifene |
| Dosage form |
Oral tablet |
| U.S. sponsor |
Pfizer Inc. |
| U.S. approval |
October 3, 2013 |
| U.S. application |
NDA 022247 |
| Primary uses |
Menopausal vasomotor symptoms; prevention of postmenopausal osteoporosis |
| Patient population |
Postmenopausal women with a uterus |
| Progestin requirement |
The product does not contain a progestin |
| Regulatory class |
Small-molecule prescription drug |
| Biosimilar pathway |
Not applicable |
Bazedoxifene is intended to protect the endometrium while permitting estrogenic activity in tissues where estrogen replacement is clinically useful. The combination is therefore positioned against conventional conjugated estrogen plus progestin regimens, not only against estrogen products.
The FDA label carries the class-wide boxed warning for estrogen therapy, including risks related to endometrial cancer, cardiovascular disorders, breast cancer and probable dementia in certain populations. The label also states that DUAVEE should not be used with additional estrogens, progestins or other selective estrogen receptor modulators [1].
What is the FDA regulatory status of DUAVEE?
DUAVEE remains an FDA-approved prescription product. The FDA approved it under NDA 022247 based on clinical data supporting vasomotor symptom reduction and bone-density preservation. FDA labeling identifies the product as appropriate for women with an intact uterus who require treatment for menopausal symptoms or osteoporosis prevention and who are not adequately served by alternatives [1].
The approval does not eliminate the regulatory constraints applying to systemic estrogen therapy. Prescribers must evaluate the lowest effective dose and shortest duration consistent with treatment objectives. The product is not indicated for cardiovascular disease prevention, and its risk-benefit profile is sensitive to age, time since menopause, personal history and treatment duration.
From a commercial perspective, FDA approval creates a differentiated position but does not produce broad label expansion. The two approved uses are concentrated in a mature menopause market with numerous generic alternatives.
When does DUAVEE lose exclusivity?
DUAVEE’s commercial exclusivity is governed by several separate rights:
- FDA regulatory exclusivity associated with the original approval.
- Orange Book-listed patents covering the composition, dosage form or methods of use.
- Patent rights covering bazedoxifene or related pharmaceutical compositions.
- Possible pediatric exclusivity or patent-term adjustments.
The original five-year New Chemical Entity exclusivity period has expired. The principal remaining barrier to U.S. generic entry is patent protection rather than FDA data exclusivity.
Public patent records identify a family assigned to Wyeth or Pfizer entities covering combinations of conjugated estrogens and bazedoxifene, including U.S. Patent No. 8,552,025. The family has been associated with DUAVEE composition protection and has an expiration date extending into the late 2020s, subject to terminal disclaimers, patent-term adjustment and Orange Book listing status [3][4].
Because patent listings can change through delisting, expiration, reissue or litigation outcomes, the relevant commercial date is the latest enforceable Orange Book-listed patent that an ANDA applicant must address. A generic applicant may challenge a patent before its nominal expiration by filing a Paragraph IV certification.
What patents protect bazedoxifene acetate and conjugated estrogens?
The DUAVEE estate is centered on combination-product protection rather than a broad, durable platform covering all estrogen replacement therapy.
| Protection category |
Commercial relevance |
| Conjugated estrogen/bazedoxifene composition patents |
Protect the active-ingredient combination and relative amounts |
| Tablet and pharmaceutical composition claims |
Address the commercial oral dosage form |
| Treatment-method claims |
Cover use in menopausal symptoms and osteoporosis-related settings |
| Bazedoxifene compound patents |
Protect the SERM active ingredient but may not independently block a DUAVEE generic |
| Manufacturing and formulation rights |
May increase development cost without independently preventing ANDA approval |
U.S. Patent No. 8,552,025 is the most frequently associated patent in public records with the conjugated estrogen/bazedoxifene combination. Its claims and expiration must be reviewed against the current Orange Book entry and the patent file history before making a launch or litigation decision [3][4].
Patent strength is moderate rather than absolute. Combination patents can be commercially useful when they cover the exact dose and formulation used in the reference product. Their value is lower when a generic applicant can design around formulation limitations while maintaining the same active ingredients and therapeutic indication. Method-of-use patents also tend to have weaker practical blocking power if a generic label can omit the patented indication or rely on physicians prescribing outside the label.
What is the Orange Book status of DUAVEE?
DUAVEE is listed in the FDA Orange Book as a prescription drug with patent information associated with the approved product. Orange Book entries identify patents that the reference sponsor represents as covering the drug, its formulation or approved use [4].
The Orange Book is central to the U.S. generic-entry analysis because an ANDA applicant must make a certification against each listed patent:
- Paragraph I: no patent information is listed.
- Paragraph II: the patent has expired.
- Paragraph III: the applicant will wait until patent expiration.
- Paragraph IV: the patent is invalid, unenforceable or not infringed.
A Paragraph IV notice can trigger a 30-month stay of FDA approval if the reference sponsor files an infringement action within the statutory period. The stay does not guarantee ultimate patent validity or prevent commercial launch if the litigation is resolved, dismissed or otherwise terminated.
The economic importance of the Orange Book estate depends on whether the listed patents cover the specific generic product and whether the sponsor can obtain an injunction or settlement that delays launch.
Are there Paragraph IV challenges to DUAVEE?
Publicly disclosed litigation and FDA records should be reviewed for the current status of any ANDA filings and notices. The existence of a Paragraph IV challenge would indicate that a generic manufacturer has accepted litigation risk and believes at least one listed patent is vulnerable or can be designed around.
For DUAVEE, generic competition is structurally plausible because:
- The product is a small molecule.
- The active ingredients are chemically defined.
- The dosage form is an oral tablet.
- Approval would proceed through an ANDA rather than the biologics license application pathway.
- A generic sponsor can pursue a bioequivalence strategy without reproducing the originator’s clinical development program.
The principal litigation issues would likely involve claim construction, written description, obviousness, enablement, infringement of composition claims, and the scope of any method-of-use claims. A generic applicant could also seek a label that omits a patented indication if the remaining indications support approval.
No biosimilar risk applies. DUAVEE is not a biologic, and the product cannot be challenged through the abbreviated biologics license application pathway.
What formulations are protected by DUAVEE patents?
The commercial formulation is an immediate-release oral tablet containing conjugated estrogens and bazedoxifene acetate at a fixed strength. Formulation protection may cover:
- The specific active-ingredient ratio.
- The tablet composition.
- Excipients or release characteristics.
- Stability and manufacturing parameters.
- Use of the fixed-dose combination in women with an intact uterus.
Formulation patents are valuable when they prevent a generic sponsor from reproducing the reference product with a bioequivalent formulation. Their value declines when the claims are narrow or when a generic can use a different excipient system and establish bioequivalence independently.
The combination does not require a complex delivery device, depot injection, transdermal system or biologic manufacturing process. That limits technical barriers to entry. Manufacturing complexity is lower than for biologics, long-acting injectables or highly specialized controlled-release products.
How does DUAVEE compare with conventional estrogen therapy?
DUAVEE competes with several therapeutic options rather than one direct substitute.
| Therapy |
Main advantage |
Main limitation relative to DUAVEE |
| Conjugated estrogens alone |
Low-cost generic availability |
Generally inappropriate for women with an intact uterus unless endometrial protection is separately addressed |
| Estrogen plus progestin |
Established treatment approach |
Progestin exposure and separate or combined regimen |
| Transdermal estrogen |
Lower hepatic first-pass exposure |
Does not inherently provide endometrial protection |
| Oral estradiol plus progestin |
Broad generic availability |
More conventional regimen and progestin exposure |
| Ospemifene |
Non-estrogen option for dyspareunia |
Does not provide the same systemic estrogen replacement profile |
| Bazedoxifene alone |
SERM activity |
Does not provide the estrogen component used for vasomotor symptoms |
| Nonhormonal therapies |
Avoid estrogen-associated risks |
Often have different efficacy and symptom coverage |
DUAVEE’s target patient is a postmenopausal woman who needs estrogenic symptom relief and has an intact uterus but prefers to avoid a progestin-containing regimen. That segment is clinically meaningful but narrower than the overall menopausal hormone-therapy population.
What is the financial trajectory for DUAVEE?
Pfizer does not report DUAVEE as a separate revenue line in its annual reports. The product is included within broader revenue categories, preventing a verified public series of annual sales, gross margin or operating profit [2].
The likely financial trajectory has four phases:
Launch and adoption phase
After the 2013 approval, uptake depended on physician awareness of the estrogen-plus-SERM concept, reimbursement and the product’s premium relative to generic hormone therapies. Launch adoption was constrained by the maturity of the menopause market and the availability of established low-cost alternatives.
Specialty and maintenance phase
The product’s commercial base is likely concentrated in women who value avoidance of progestin or who have a specific clinical preference for the fixed-dose combination. Refill persistence is important because hormone therapy can be continued over multiple years, but treatment discontinuation is common because of risk concerns, symptom improvement, changing clinical guidance or insurance barriers.
Pre-generic erosion phase
As patent risk becomes more visible, payers and prescribers have less incentive to adopt a premium branded product. Pharmacy benefit managers may impose prior authorization, higher copay tiers or step therapy through generic estrogen products. This reduces net price and limits new-patient growth.
Generic-entry phase
Generic entry would likely cause rapid price erosion. The degree of volume retention would depend on substitution rules, the number of approved ANDAs, payer coverage and whether the generic carries the full set of approved indications. Fixed-dose combinations can retain some brand value if patients and prescribers perceive the formulation as clinically distinct, but automatic substitution generally favors the generic.
What generic entry risks exist for DUAVEE?
The generic-entry risk is high after the final enforceable composition or formulation patent expires or is invalidated.
Key risk factors include:
- Small-molecule active ingredients.
- Conventional oral tablet technology.
- No biologic comparability burden.
- Availability of generic conjugated estrogens and generic hormone therapies.
- Limited manufacturing differentiation.
- Lack of separately disclosed high-growth revenue protection.
- Potential for multiple ANDA applicants once the principal patents are vulnerable.
A first-filer Paragraph IV applicant may obtain 180 days of generic exclusivity under the Hatch-Waxman framework, depending on the filing and forfeiture status. A successful early challenger could enter before full patent expiry if it defeats the relevant patent or reaches a settlement permitting an earlier launch.
What patent litigation and settlement issues affect DUAVEE?
A DUAVEE patent dispute would be commercially significant only if it involves the latest blocking patent and a credible generic applicant. Older patents covering bazedoxifene alone may have limited practical value if they do not cover the approved fixed-dose product.
Settlement agreements could establish:
- A licensed generic launch date.
- An authorized generic arrangement.
- A royalty or supply agreement.
- A restriction on the generic’s launch until a negotiated date.
- An agreement to withdraw or terminate litigation.
The absence of a public settlement does not establish that generic entry is unavailable. It means the commercial path remains controlled by patent status, ANDA filings, litigation and FDA approval timing.
Which companies are challenging or competing with DUAVEE?
The competitive field includes generic estrogen manufacturers, hormone-therapy companies and nonhormonal menopause-treatment developers. Likely generic competitors include companies with established ANDA capabilities in oral hormone products, such as Teva, Viatris, Endo, Amneal, Dr. Reddy’s, Lupin and multiple private-label manufacturers. A specific company should be treated as a confirmed challenger only when an ANDA filing, Paragraph IV notice or litigation complaint is publicly documented.
Branded competition includes products based on conjugated estrogens, oral estradiol, transdermal estrogen and estrogen-progestin combinations. Newer nonhormonal products for vasomotor symptoms, including neurokinin-3 receptor antagonists, can reduce the addressable market for systemic estrogen therapy without directly competing on formulation.
How strong is the DUAVEE patent estate?
The estate is commercially useful but not unusually strong.
Its strengths are the fixed-dose combination, a defined target population and potential coverage of the specific approved tablet. Its weaknesses are the small-molecule nature of the product, conventional manufacturing, potential design-around opportunities, and the limited ability of method-of-use claims to block all generic prescribing.
The estate is strongest if the key composition patent remains valid, enforceable and difficult to design around. It is weakest if the principal claim depends on narrow formulation limitations or if a generic can establish bioequivalence using a different formulation.
Key Takeaways
- DUAVEE combines conjugated estrogens 0.45 mg with bazedoxifene 20 mg and is approved for menopausal vasomotor symptoms and osteoporosis prevention.
- Pfizer does not separately disclose DUAVEE revenue, so product-level financial performance cannot be verified from public company filings.
- The product’s commercial differentiation is avoidance of a progestin in women with an intact uterus.
- Original FDA regulatory exclusivity has expired; patent protection is the principal remaining barrier to generic entry.
- U.S. Patent No. 8,552,025 is publicly associated with the conjugated estrogen/bazedoxifene combination and extends into the late 2020s, subject to Orange Book and patent-record confirmation.
- DUAVEE faces high long-term generic risk because it is a small-molecule oral tablet with no biologic manufacturing barrier.
- Biosimilar competition is not relevant.
- Revenue exposure is likely limited relative to Pfizer’s major products because DUAVEE is not separately reported and competes in a mature, price-sensitive market.
FAQs
Is DUAVEE the same as bazedoxifene alone?
No. DUAVEE contains bazedoxifene acetate plus conjugated estrogens. Bazedoxifene alone is a selective estrogen receptor modulator and does not provide the same estrogen-replacement formulation.
Can generic conjugated estrogens substitute for DUAVEE?
Not automatically. Generic conjugated estrogens do not contain bazedoxifene and generally do not provide the same fixed-dose combination or endometrial-protection strategy.
Does DUAVEE have biosimilar competition?
No. DUAVEE is a small-molecule drug. Any generic competitor would use the ANDA pathway rather than the biosimilar pathway.
Why is DUAVEE commercially differentiated from Premarin?
DUAVEE combines conjugated estrogens with bazedoxifene, while Premarin contains conjugated estrogens alone. The combination is designed for women with an intact uterus who need estrogen therapy without adding a progestin.
What would happen to DUAVEE after generic entry?
Generic entry would likely reduce net price, increase payer substitution and compress Pfizer’s product-level revenue. Brand retention would depend on formulary treatment, patient persistence and whether generic products match the reference product’s approved indications and fixed-dose formulation.
References
- U.S. Food and Drug Administration. (2023). DUAVEE prescribing information. https://www.accessdata.fda.gov
- Pfizer Inc. (2024). 2023 annual report. https://www.pfizer.com/investors/financial-reports
- U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,552,025. https://patents.google.com/patent/US8552025
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
